Indivior Announces The Publication Of New Data On The Comparative Effectiveness Of Intranasal Nalmefene And IN Naloxone 4 mg In A Translational Model Assessing The Impact Of A Synthetic Opioid Overdose On Respiratory Depression And Cardiac Arrest In The 'Frontiers in Psychiatry'
Portfolio Pulse from Benzinga Newsdesk
Indivior PLC (NASDAQ:INDV) has published new data in 'Frontiers in Psychiatry' showing that its OPVEE (nalmefene) nasal spray is more effective than IN naloxone in reducing the incidence of cardiac arrest following synthetic opioid overdoses.
June 18, 2024 | 7:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indivior PLC's new data shows that its OPVEE nasal spray is significantly more effective than IN naloxone in reducing cardiac arrest from synthetic opioid overdoses. This could boost investor confidence and potentially increase stock prices.
The publication of data demonstrating the superior effectiveness of Indivior's OPVEE nasal spray over IN naloxone in reducing cardiac arrest from synthetic opioid overdoses is likely to boost investor confidence. This could lead to a positive short-term impact on Indivior's stock price as the market reacts to the potential for increased demand and market share for OPVEE.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100